Literature DB >> 24756173

Non-Medical Prescription Stimulant Use in Graduate Students: Relationship With Academic Self-Efficacy and Psychological Variables.

Genevieve Verdi1, Lisa L Weyandt2, Brynheld Martinez Zavras2.   

Abstract

OBJECTIVE: The objective of this study was to examine graduate students' non-medical use of prescription stimulant medication, and the relationship between non-medical use of prescription stimulants with academic self-efficacy, psychological factors (i.e., anxiety, depression, and stress), and internal restlessness.
METHOD: The sample consisted of 807 graduate students from universities located in five geographic regions of the United States.
RESULTS: Past-year rates of self-reported non-medical use were determined to be 5.9%, with overall lifetime prevalence of 17.5%. Observed self-reported non-medical use of prescription stimulant medications was significantly correlated with self-reported levels of anxiety and stress, various aspects of internal restlessness, and perceived safety of the medications.
CONCLUSION: Findings support graduate students' motivations of non-medical prescription stimulant use to be both academic and social in nature. Effective prevention and education efforts are needed to help address the non-medical use of prescription stimulants by graduate students on university campuses.
© The Author(s) 2014.

Entities:  

Keywords:  ADHD; adult; stimulant misuse

Mesh:

Substances:

Year:  2014        PMID: 24756173     DOI: 10.1177/1087054714529816

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  8 in total

Review 1.  Prescription stimulant medication misuse: Where are we and where do we go from here?

Authors:  Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Emma S Rathkey; Alison McCallum
Journal:  Exp Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.157

Review 2.  Attention-deficit/hyperactivity disorder in postsecondary students.

Authors:  Kevin Nugent; Wallace Smart
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-26       Impact factor: 2.570

Review 3.  Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.

Authors:  Johanna Daubner; Muhammad Imran Arshaad; Christina Henseler; Jürgen Hescheler; Dan Ehninger; Karl Broich; Oliver Rawashdeh; Anna Papazoglou; Marco Weiergräber
Journal:  Neural Plast       Date:  2021-01-13       Impact factor: 3.599

4.  Increasing prevalence of illicit drug use among employees at Swedish workplaces over a 25-year period.

Authors:  Kristin Feltmann; Tomas Villén; Olof Beck; Johanna Gripenberg
Journal:  Eur J Public Health       Date:  2022-10-03       Impact factor: 4.424

Review 5.  Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants.

Authors:  Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Brynheld Martinez Zavras; Ben Kuhar
Journal:  Psychol Res Behav Manag       Date:  2014-09-09

Review 6.  Prescription Drug Misuse: Taking a Lifespan Perspective.

Authors:  Ty S Schepis; Dalton L Klare; Jason A Ford; Sean Esteban McCabe
Journal:  Subst Abuse       Date:  2020-03-05

7.  Potential risk groups and psychological, psychosocial, and health behavioral predictors of pharmacological neuroenhancement among university students in Germany.

Authors:  Sebastian Heller; Ana Nanette Tibubos; Thilo A Hoff; Antonia M Werner; Jennifer L Reichel; Lina M Mülder; Markus Schäfer; Daniel Pfirrmann; Birgit Stark; Thomas Rigotti; Perikles Simon; Manfred E Beutel; Stephan Letzel; Pavel Dietz
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379

8.  Prevalence and Correlates of Prescription Drug Misuse in a Nationwide Population Survey in Taiwan.

Authors:  Shu-Wei Liu; Chia-Yi Wu; Ming-Been Lee; Ming-Chi Huang; Chia-Ta Chan; Chun-Ying Chen
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.